CAR T-Cell Therapy and COVID-19 Vaccinations: Muhammad Bilal Abid, MD, MRCP

Video

The assistant professor of medicine from Medical College of Wisconsin discussed the potential impact of CAR T-cell therapy on the efficacy of COVID-19 vaccinations.

This content originally appeared on our sister site, OncLive.

OncLive spoke with Muhammad Bilal Abid, MD, MRCP, assistant professor of medicine, Divisions of Hematology/Oncology and Infectious Diseases, Medical College of Wisconsin, to learn more about the potential impact of CAR T-cell therapy on the efficacy of COVID-19 vaccinations.

Abid discussed how CAR T-cell therapy may lessen patients' response to COVID-19 vaccinations, and that patients that undergo treatment should be revaccinated for COVID-19 following infusion.

Additionally, it has been shown that if the patient received the COVID-19 vaccine within 6 months of receiving CAR T-cell infusion, response rates were not as favorable, Abid explains. Patients who received the vaccination more than 6 months after infusion have improved response rates, likely because they have better immune reconstitution, Abid concludes.

Recent Videos
David Barrett, JD, the chief executive officer of ASGCT
Georg Schett, MD, vice president research and chair of internal medicine at the University of Erlangen – Nuremberg
David Barrett, JD, the chief executive officer of ASGCT
Bhagirathbhai R. Dholaria, MD, an associate professor of medicine in malignant hematology & stem cell transplantation at Vanderbilt University Medical Center
Caroline Diorio, MD, FRCPC, FAAP, an attending physician at the Cancer Center at Children's Hospital of Philadelphia
R. Nolan Townsend; Sandi See Tai, MD; Kim G. Johnson, MD
Daniela van Eickels, MD, PhD, MPH, the vice president and head of medical affairs for Bristol Myers Squibb’s Cell Therapy Organization
Paul Melmeyer, MPP, the executive vice president of public policy & advocacy at MDA
Daniela van Eickels, MD, PhD, MPH, the vice president and head of medical affairs for Bristol Myers Squibb’s Cell Therapy Organization
Related Content
© 2024 MJH Life Sciences

All rights reserved.